Related Experiment Video

Updated: Jun 7, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.5K

Factor XI and XIa inhibition: a new approach to anticoagulant therapy

Mark Anthony Sammut1, Nadir Elamin2, Robert F Storey3

  • 1Specialist Registrar in Cardiology and Clinical Research Fellow.

The British Journal of Cardiology
|November 18, 2024
PubMed

Insights

Factor XI (FXI) and FXIa inhibition offers a promising approach to prevent thrombosis with a reduced risk of bleeding. This review details FXI/FXIa inhibitors and their potential in treating thromboembolic diseases.

Area of Science:

  • Hemostasis and Thrombosis
  • Pharmacology
  • Clinical Trials

Background:

  • Factor XI (FXI) deficiency is associated with protection from thrombotic events and minimal bleeding.
  • Current anticoagulants carry an inherent risk of bleeding, creating a need for safer alternatives.
  • Targeting FXI/FXIa offers a potential strategy to decouple thrombosis management from bleeding risk.

Purpose of the Study:

  • To review the physiological rationale for FXI/FXIa inhibition.
  • To describe the pharmacological properties of existing FXI/FXIa inhibitors.
  • To explore the potential clinical applications of these agents in thromboembolic pathologies.

Main Methods:

  • Review of physiological mechanisms of Factor XI activation and coagulation.
  • Analysis of pharmacological profiles of FXI/FXIa inhibitors.
  • Examination of data from Phase II clinical trials comparing FXI/FXIa inhibitors to placebo or current anticoagulants.

Main Results:

  • FXI/FXIa inhibition is physiologically sound for antithrombotic therapy.
  • Several FXI/FXIa inhibitors demonstrate promising pharmacological properties.
  • Phase II trials suggest potential efficacy in thromboembolic conditions with a favorable bleeding profile.

Conclusions:

  • FXI/FXIa inhibitors represent a novel therapeutic class for thromboembolic disorders.
  • These agents may offer an improved benefit-risk profile compared to existing anticoagulants.
  • Further clinical investigation is warranted to establish the role of FXI/FXIa inhibitors in patient care.
Keywords:
acute coronary syndromesanticoagulant therapyatrial fibrillationbleedingfactor XIfactor XIavenous thromboembolism

More Related Videos

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
471
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.7K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.1K